Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Non Operating Income of -$61.6 million for Q1 2026, up 2.01% year-over-year from -$60.4 million in Q1 2025, and down 8.45% quarter-over-quarter from -$56.8 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Non Operating Income history runs 10 years deep, the most recent figure standing at -$61.6 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 2.01% year-over-year to -$61.6 million; the TTM figure through Mar 2026 stood at -$253.6 million (up 16.14% YoY), while the FY2025 annual figure was -$254.9 million, up 16.25% from the prior year.
- Non Operating Income for Q1 2026 stood at -$61.6 million, down from -$56.8 million in the prior quarter.
- The five-year high for Non Operating Income was -$33.2 million in Q1 2022, with the low at -$93.6 million in Q4 2023.
- The 5-year median for Non Operating Income is -$59.7 million (2025), against an average of -$59.9 million.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income plunged 123.57% in 2023, then surged 37.66% in 2025.
- Amneal Pharmaceuticals' Non Operating Income stood at -$41.8 million in 2022, then slumped by 123.57% to -$93.6 million in 2023, then climbed by 2.62% to -$91.1 million in 2024, then surged by 37.66% to -$56.8 million in 2025, then retreated by 8.45% to -$61.6 million in 2026.
- Business Quant data shows AMRX's Non Operating Income at -$61.6 million in Q1 2026, -$56.8 million in Q4 2025, and -$75.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Amneal Pharmaceuticals | 5.71 Bn | 5.58 Bn | 334.51 Mn | -58.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.78 Mn |
| Mar 31, 2026 | -61.60 Mn |
| Dec 31, 2025 | -56.80 Mn |
| Sep 30, 2025 | -75.57 Mn |
| Jun 30, 2025 | -59.66 Mn |
| Mar 31, 2025 | -62.86 Mn |
| Dec 31, 2024 | -91.11 Mn |
| Sep 30, 2024 | -73.39 Mn |
| Jun 30, 2024 | -75.07 Mn |
| Mar 31, 2024 | -64.78 Mn |
| Dec 31, 2023 | -93.56 Mn |
| Sep 30, 2023 | -52.69 Mn |
| Jun 30, 2023 | -50.42 Mn |
| Mar 31, 2023 | -49.32 Mn |
| Dec 31, 2022 | -41.85 Mn |
| Sep 30, 2022 | -42.17 Mn |
| Jun 30, 2022 | -34.11 Mn |
| Mar 31, 2022 | -33.23 Mn |
| Dec 31, 2021 | -27.49 Mn |
| Sep 30, 2021 | -30.56 Mn |